Lightspeed China Partners

The funds will be used in research and development, in the verification of its existing digital biomarker pipeline, to cooperate with international scientific research bodies and to upgrade its digital biomarker R&D platform, it added

Data is the core of digital medicine, and precision medicine in the future will be driven by data, said Chief Executive Officer Chen Si Through its pioneering work on digital biomarkers, Luca will make medical services more efficient and accessible and bring more benefits to patients through technological innovations

Digital technology innovation will penetrate into all aspects of healthcare, said Gao Jiankai, partner at Lightspeed China The fundamental and key technology in the field is to dig out disease-related digital biomarkers Luca’s team has great in-depth knowledge and strong R&D capabilities in this regard, he added

Luca, which was set up last year, focuses on the development of digital biomarkers in respiratory, neurodegenerative and cardiovascular disease It works with a network of big pharmaceutical companies, medical systems and insurance companies, and uses a combination of algorithms and wearable devices to screen, diagnose and treat diseases

Log in to Yicai Global

We sent you a code

You'll need a password

Find your Yicai Global account

Enter your new password

Enter your new password again